Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Income from Continuing Operations (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Income from Continuing Operations for 11 consecutive years, with 26805.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 100.79% year-over-year to 26805.0, compared with a TTM value of 8577131.0 through Sep 2025, down 273.44%, and an annual FY2024 reading of 3559738.0, up 128.45% over the prior year.
  • Income from Continuing Operations was 26805.0 for Q3 2025 at Kiora Pharmaceuticals, up from 2152459.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13453207.0 in Q1 2024 and bottomed at 14391768.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2057502.76, with a median of 2221646.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations plummeted 5345.16% in 2022, then surged 801.91% in 2024.
  • Year by year, Income from Continuing Operations stood at 14391768.0 in 2021, then surged by 74.27% to 3703035.0 in 2022, then grew by 22.42% to 2872830.0 in 2023, then plummeted by 48.23% to 4258497.0 in 2024, then soared by 100.63% to 26805.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KPRX at 26805.0 in Q3 2025, 2152459.0 in Q2 2025, and 2192980.0 in Q1 2025.